Cardiovascular events occur independently of high on-aspirin platelet reactivity and residual COX-1 activity in stable cardiovascular patients

Summary

Several studies have indicated that approximately 25% of patients treated with aspirin exhibit high on-treatment platelet reactivity (HTPR), which is potentially associated with cardiovascular events (CVEs). However, this association is still controversial, since the mechanisms by which HTPR contributes to CVEs remain unclear and a no standardised definition of HTPR has been established. To determine whether HTPR is associated with CVE recurrence and what type of assay would best predict CVE recurrence, we conducted a multicentre prospective cohort study of 592 stable cardiovascular outpatients treated with aspirin monotherapy for secondary prevention. Their HTPR was determined by arachidonic acid- or collagen-induced aggregation assays using two different agonist concentrations. Residual cyclooxygenase (COX)-1 activity was assessed by measuring serum thromboxane (TX)B₂ or urinary 11-dehydro TXB₂. Shear-induced platelet thrombus formation was also examined. We followed all patients for two years to evaluate how these seven indexes were related to the recurrence of CVEs (cerebral infarction, transient ischaemic attack, myocardial infarction, unstable angina, revascularisation, other arterial thrombosis, or cardiovascular death). Of 583 patients eligible for the analysis, CVEs occurred in 69 (11.8%). A Cox regression model identified several classical risk factors associated with CVEs. However, neither HTPR nor high residual COX-1 activity was significantly associated with CVEs, even by applying cut-off values suggested in previous reports or a receiver-operating characteristic analysis. In conclusion, recurrence of CVEs occurred independently of HTPR and residual COX-1 activity. Thus, our findings do not support the use of platelet or COX-1 functional testing for predicting clinical outcomes in stable cardiovascular patients.

Supplementary Material to this article is available at www.thrombosis-online.com.

Keywords

Aspirin - cardiovascular diseases - platelets - secondary prevention

• References

• 1 Davi G, Patrono C.. Platelet activation and atherothrombosis. N Engl J Med 2007; 357: 2482-2494.
• 2 Patrono C, Garcia Rodriguez LA, Landolfi R. et al. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005; 353: 2373-2383.
• 3 Baigent C, Blackwell L, Collins R. et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-1860.
• 4 Eikelboom JW, Hirsh J, Spencer FA. et al. Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e89S-119S.
• 5 Franchi F, Angiolillo DJ.. Novel antiplatelet agents in acute coronary syndrome. Nat Rev Cardiol 2015; 12: 30-47.
• 6 Fuster V, Sweeny JM.. Aspirin: a historical and contemporary therapeutic overview. Circulation 2011; 123: 768-778.
• 7 Maree AO, Curtin RJ, Chubb A. et al. Cyclooxygenase-1 haplotype modulates platelet response to aspirin. J Thromb Haemost 2005; 3: 2340-2345.
• 8 Gurbel PA, Bliden KP, DiChiara J. et al. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation 2007; 115: 3156-3164.
• 9 Snoep JD, Hovens MM, Eikenboom JC. et al. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med 2007; 167: 1593-1599.
• 10 Hovens MM, Snoep JD, Eikenboom JC. et al. Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review. Am Heart J 2007; 153: 175-181.
• 11 Krasopoulos G, Brister SJ, Beattie WS. et al. Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysis. Br Med J 2008; 336: 195-198.
• 12 Reny JL, De Moerloose P, Dauzat M. et al. Use of the PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a systematic review and meta-analysis. J Thromb Haemost 2008; 6: 444-450.
• 13 Wisman PP, Roest M, Asselbergs FW. et al. Platelet-reactivity tests identify patients at risk of secondary cardiovascular events: a systematic review and meta-analysis. J Thromb Haemost 2014; 12: 736-747.
• 14 Eikelboom JW, Hirsh J, Weitz JI. et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105: 1650-1655.
• 15 Gum PA, Kottke-Marchant K, Welsh PA. et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003; 41: 961-965.
• 16 Ohmori T, Yatomi Y, Nonaka T. et al. Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients. J Thromb Haemost 2006; 4: 1271-1278.
• 17 Eikelboom JW, Hankey GJ, Thom J. et al. Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. Circulation 2008; 118: 1705-1712.
• 18 Frelinger 3rd AL, Li Y, Linden MD. et al. Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterisation. Circulation 2009; 120: 2586-2596.
• 19 Beigel R, Hod H, Fefer P. et al. Relation of aspirin failure to clinical outcome and to platelet response to aspirin in patients with acute myocardial infarction. Am J Cardiol 2011; 107: 339-342.
• 20 Reny JL, Berdague P, Poncet A. et al. Antiplatelet drug response status does not predict recurrent ischaemic events in stable cardiovascular patients: results of the Antiplatelet Drug Resistances and Ischaemic Events study. Circulation 2012; 125: 3201-3210.
• 21 Pettersen AA, Seljeflot I, Abdelnoor M. et al. High On-Aspirin Platelet Reactivity and Clinical Outcome in Patients With Stable Coronary Artery Disease: Results From ASCET(Aspirin Nonresponsiveness and Clopidogrel Endpoint Trial). J Am Heart Assoc 2012; 1: e000703.
• 22 Kameda S, Sakata T, Kokubo Y. et al. Association of platelet aggregation with lipid levels in the Japanese population: the Suita study. J Atheroscler Thromb 2011; 18: 560-567.
• 23 Armstrong PC, Truss NJ, Ali FY. et al. Aspirin and the in vitro linear relationship between thromboxane A2-mediated platelet aggregation and platelet production of thromboxane A2. J Thromb Haemost 2008; 6: 1933-1943.
• 24 Tsuji S, Sugimoto M, Miyata S. et al. Real-time analysis of mural thrombus formation in various platelet aggregation disorders: distinct shear-dependent roles of platelet receptors and adhesive proteins under flow. Blood 1999; 94: 968-975.
• 25 Chen WH, Lee PY, Ng W. et al. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 2004; 43: 1122-1126.
• 26 Campbell CL, Steinhubl SR.. Variability in response to aspirin: do we understand the clinical relevance?. J Thromb Haemost 2005; 3: 665-669.
• 27 Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002; 324: 71-86.
• 28 Gum PA, Kottke-Marchant K, Poggio ED. et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001; 88: 230-235.
• 29 Breet NJ, van Werkum JW, Bouman HJ. et al. High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention. Heart 2011; 97: 983-990.
• 30 Santilli F, Rocca B, De Cristofaro R. et al. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin „resistance”. J Am Coll Cardiol 2009; 53: 667-677.
• 31 Frelinger AL, Li Y, Linden MD. et al. Aspirin 'resistance’: role of pre-existent platelet reactivity and correlation between tests. J Thromb Haemost 2008; 6: 2035-2044.
• 32 Fitzgerald R, Pirmohamed M.. Aspirin resistance: effect of clinical, biochemical and genetic factors. Pharmacol Ther 2011; 130: 213-225.
• 33 Guthikonda S, Lev EI, Patel R. et al. Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin. J Thromb Haemost 2007; 5: 490-496.
• 34 Freynhofer MK, Gruber SC, Grove EL. et al. Antiplatelet drugs in patients with enhanced platelet turnover: biomarkers versus platelet function testing. Thromb Haemost 2015; 114: 459-468.
• 35 Grove EL, Hvas AM, Johnsen HL. et al. A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease. Thromb Haemost 2010; 103: 1245-1253.
• 36 Peace A, McCall M, Tedesco T. et al. The role of weight and enteric coating on aspirin response in cardiovascular patients. J Thromb Haemost 2010; 8: 2323-2325.
• 37 Cox D, Maree AO, Dooley M. et al. Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers. Stroke 2006; 37: 2153-2158.
• 38 Andersen K, Hurlen M, Arnesen H. et al. Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res 2002; 108: 37-42.
• 39 Hedegaard SS, Hvas AM, Grove EL. et al. Optical platelet aggregation versus thromboxane metabolites in healthy individuals and patients with stable coronary artery disease after low-dose aspirin administration. Thromb Res 2009; 124: 96-100.